A Phase 2 Clinical Study of Evaluation of Recombinant Anti-PD-1 Humanized Monoclonal Antibody Injection (609A) Combined With Doxorubicin Hydrochloride in the Treatment of Metastatic/Unresectable Non-specific Soft Tissue Sarcoma

NCT05138146 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

70

Enrollment

INDUSTRY

Sponsor class

Conditions

Sarcoma, Soft Tissue

Interventions

DRUG: 609A
DRUG: doxorubicin hydrochloride

Sponsor

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.